exocrine pancreatic insufficiency after acute pancreatitis and pancreatic enzyme replacement therapy

Conditions: Acute Pancreatitis; Exocrine Pancreatic Insufficiency; Gut Microbiota; Immunology

Summary: acute pancreatitis represents an acute inflammatory process of the pancreas, which undergoes local and systemic complications, associated with non-negligible morbidity and mortality, and significant economic and quality of life impact. even after the recovery phase, the development and persistence of sequelae from the inflammatory/necrotic process, including exocrine and endocrine pancreatic insufficiencies, are frequent. although well documented as consequence of other pancreatic conditions, exocrine pancreatic insufficiency (epi) after acute pancreatitis is poorly studied and probably underdiagnosed. the prevalence, diagnosis, independent risk factors and therapeutic approaches for epi after acute pancreatitis need further investigation. recent evidence suggests the involvement of the pancreas-intestinal axis and immunological dysfunction in several pancreatic pathologies, although their role in the development of epi after acute pancreatitis is still scarce. pancreatic enzyme replacement therapy (pert) is the only treatment currently available in epi, but the timing for start and duration of this therapy in acute pancreatitis remain to be established. this study have the following objectives: to determine the prevalence, clinical, analytical and nutritional biomarkers and duration of epi after acute pancreatitis, as well as changes in gut microbiota and immunologic response, and quality of life in epi and response to pert after acute pancreatitis; and to determine the prevalence and biomarkers associated with endocrine pancreatic insufficiency following acute pancreatitis and the presence of gut dysbiosis and immunologic changes in acute pancreatitis according to its severity.

introduction: acute pancreatitis represents an acute inflammatory process of the pancreas, which undergoes local and systemic complications, associated with non-negligible morbidity and mortality, and significant economic and quality of life impact. even after the recovery phase, the development and persistence of sequelae from the inflammatory/necrotic process, including exocrine and endocrine pancreatic insufficiencies, are frequent. although well documented as consequence of other pancreatic conditions, exocrine pancreatic insufficiency (epi) after acute pancreatitis is poorly studied and probably underdiagnosed. the prevalence, diagnosis, independent risk factors and therapeutic approaches for epi after acute pancreatitis need further investigation. recent evidence suggests the involvement of the pancreas-intestinal axis and immunological dysfunction in several pancreatic pathologies, although their role in the development of epi after acute pancreatitis is still scarce. pancreatic enzyme replacement therapy (pert) is the only treatment currently available in epi, but the timing for start and duration of this therapy in acute pancreatitis remain to be established. objectives: primary objectives: to determine the prevalence, clinical, analytical and nutritional biomarkers and duration of epi after acute pancreatitis, as well as changes in gut microbiota and immunologic response, and quality of life in epi and response to pert after acute pancreatitis. secondary objectives: to determine the prevalence and biomarkers associated with endocrine pancreatic insufficiency following acute pancreatitis and the presence of gut dysbiosis and immunologic changes in acute pancreatitis according to its severity. methods: prospective longitudinal study of total of patients consecutively admitted to the gastroenterology department of coimbra hospital and university centre with acute pancreatitis diagnosis and double-blind randomized placebo-controlled clinical trial of pert in patients developing epi after acute pancreatitis. this study will be conducted in 4 phases: phase 1 - recruitment of patients with acute pancreatitis and stratification of them according to the severity of acute pancreatitis and development of epi (12-month followup), diagnosed by fecal elastase-1, 13c-labeled mixed triglyceride breath test assessing exocrine pancreatic function and comparison of them with 72-hour fecal fat quantification, as gold standard; phase 2 - double-blind randomized placebo-controlled trial in patients with epi after acute pancreatitis for pert with assessment of efficacy and safety of this therapy at 1 and 6 months post-randomization; phase 3 - evaluation of richness, diversity and uniformity of gut microbiota by dna sequencing using the hypervariable region of the 16s ribosomal rna gene as a taxonomic identification marker and assessment of quality of life using sf-36 and qlc-c30-v.3 scales (validated versions for the portuguese population) in epi patients after acute pancreatitis, and the impact of pert on clinical course, gut dysbiosis and quality of life of patients (at the diagnosis of acute pancreatitis, epi and after pert); and phase 4 - analysis of immunological changes through the study of cell populations by flow cytometry (cd4+, cd8+, b-cell, t-cell, natural killer cells, cells ratio) and cytokines, chemokines and growth factors by xmap/luminex, at the diagnosis of acute pancreatitis, epi and after pert. expected results, impact and scientific outputs: data on the prevalence of epi after acute pancreatitis in its different forms of severity and the role of gut dysbiosis and immunologic changes remains unclear. it's expected that an adequate and timely diagnosis of this clinical condition will allow an early start of therapy with positive impact on clinical course, immunologic and gut homeostasis, survival and quality of life. with this study we expect to obtain a prevalence of epi at admission of 25-62%, which should decrease during followup. alcoholic etiology, severity of acute pancreatitis and the presence of pancreatic necrosis should be positively associated with the presence of epi after acute pancreatitis. the prevalence of endocrine pancreatic insufficiency (pre-diabetes or diabetes mellitus) should be up to 40%. nutritional deficits (single or multiple), breath test assessing exocrine pancreatic function and fecal elastase-1 are also expected to be positively associated with the development of epi. it's expected that patients with acute pancreatitis developing epi will have significant changes on gut microbiota and immunologic response, and pert and/or gut microbiota modulating therapy, including prebiotics, probiotics, symbiotics and fecal microbiota transplantation, and probably targeted immunotherapies may have a beneficial impact on all patients or groups at risk, such as epi, severe or necrotizing acute pancreatitis by reverting gut and immunologic dysbiosis, and improving quality of life.

Eligibility criteria:
inclusion criteria: * definitive diagnosis of acute pancreatitis, according to revised atlanta criteria 2012. exclusion criteria: * age \<18years * history of allergy, hypersensitivity or contraindication to use of pert * prior acute pancreatitis * other causes that may occur with epi, including celiac disease, diabetic gastroparesis, chronic pancreatitis, cystic fibrosis, pancreatic neoplasia, ampulloma, somatostatinoma, somatostatin analog therapy, small bowel pathology, inflammatory bowel disease, and rare diseases associated with exocrine pancreatic insufficiency (zollinger-ellison syndrome, shwachman-diamond syndrome, johanson-blizzard syndrome) * prior gastrointestinal or pancreatic surgery or endoscopic/surgical therapy for obesity * medication with orlistat or acarbose * respiratory pathology (severe chronic obstructive pulmonary disease), hepatic (child-pugh c cirrhosis) or biliary (obstructive jaundice) severe pathology * non-compliance for pert (when indicated) * uncontrolled thyroid pathology * refusal/incapacity to give informed consent * follow-up period \<12months after acute pancreatitis diagnosis